Efficacy, safety, and immunogenicity of a Vero-cell-culture-derived trivalent influenza vaccine: a multicentre, double-blind, randomised, placebo-controlled trial
- 1 February 2011
- journal article
- research article
- Published by Elsevier BV in The Lancet
- Vol. 377 (9767), 751-759
- https://doi.org/10.1016/s0140-6736(10)62228-3
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- A Whole Virus Pandemic Influenza H1N1 Vaccine Is Highly Immunogenic and Protective in Active Immunization and Passive Protection Mouse ModelsPLOS ONE, 2010
- Efficacy of Inactivated Split‐Virus Influenza Vaccine against Culture‐Confirmed Influenza in Healthy Adults: A Prospective, Randomized, Placebo‐Controlled TrialThe Journal of Infectious Diseases, 2009
- Continuous cell lines as a production system for influenza vaccinesExpert Review of Vaccines, 2009
- A Cell Culture (Vero)–Derived H5N1 Whole‐Virus Vaccine Induces Cross‐Reactive Memory ResponsesThe Journal of Infectious Diseases, 2009
- Vero cell platform in vaccine production: moving towards cell culture-based viral vaccinesExpert Review of Vaccines, 2009
- Effectiveness of Inactivated Influenza Vaccines Varied Substantially with Antigenic Match from the 2004–2005 Season to the 2006–2007 SeasonThe Journal of Infectious Diseases, 2009
- Influenza vaccine strain selection and recent studies on the global migration of seasonal influenza virusesVaccine, 2008
- Seasonal inactivated influenza virus vaccinesVaccine, 2008
- A Clinical Trial of a Whole-Virus H5N1 Vaccine Derived from Cell CultureNew England Journal of Medicine, 2008
- Algorithm AS 183: An Efficient and Portable Pseudo-Random Number GeneratorJournal of the Royal Statistical Society Series C: Applied Statistics, 1982